Mesoblast Stock Performance
| MESO Stock | USD 13.16 0.03 0.23% |
The company secures a Beta (Market Risk) of 1.02, which conveys a somewhat significant risk relative to the market. Mesoblast returns are very sensitive to returns on the market. As the market goes up or down, Mesoblast is expected to follow. At this point, Mesoblast has a negative expected return of -0.28%. Please make sure to verify Mesoblast's potential upside, as well as the relationship between the kurtosis and day typical price , to decide if Mesoblast performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Insignificant
Weak | Strong |
Over the last 90 days Mesoblast has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of inconsistent performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in April 2025. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
Actual Historical Performance (%)
One Day Return (0.23) | Five Day Return (0.90) | Year To Date Return (36.15) | Ten Year Return (55.84) | All Time Return 324.52 |
Last Split Factor 1:2 | Last Split Date 2024-01-10 |
1 | Mesoblast After Approval Stock Is Buoyant Now, But Unpredictable Overall - Seeking Alpha | 12/30/2024 |
2 | Ryoncil Commercial Launch Update and Product Pipeline | 01/31/2025 |
3 | Is Mesoblast Limited the Best Long Term ASX Stock to Buy Now | 02/11/2025 |
4 | Dr. Gregory George MD PhD Joins Mesoblast Board | 02/24/2025 |
5 | Mesoblast Sets Ryoncil Price Based on Economic Value of Treatme | 02/26/2025 |
6 | Mesoblast share price rips 12 percent on financial and operational updates | 02/27/2025 |
7 | Mesoblast Added to SPASX 200 INDEX | 03/06/2025 |
8 | Mesoblast Ltd Joins SPASX 200 Index | 03/07/2025 |
9 | Investors push Mesoblast 18 percent lower this week, companys increasing losses might be to blame | 03/10/2025 |
10 | Ryoncil Product Information Now Available in All Four Major Dru | 03/14/2025 |
| Begin Period Cash Flow | 71.3 M |
Mesoblast |
Mesoblast Relative Risk vs. Return Landscape
If you would invest 1,676 in Mesoblast on December 19, 2024 and sell it today you would lose (360.00) from holding Mesoblast or give up 21.48% of portfolio value over 90 days. Mesoblast is currently does not generate positive expected returns and assumes 5.4876% risk (volatility on return distribution) over the 90 days horizon. In different words, 48% of stocks are less volatile than Mesoblast, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Mesoblast Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Mesoblast's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Mesoblast, and traders can use it to determine the average amount a Mesoblast's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0512
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | MESO |
Estimated Market Risk
| 5.49 actual daily | 48 52% of assets are more volatile |
Expected Return
| -0.28 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.05 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Mesoblast is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Mesoblast by adding Mesoblast to a well-diversified portfolio.
Mesoblast Fundamentals Growth
Mesoblast Stock prices reflect investors' perceptions of the future prospects and financial health of Mesoblast, and Mesoblast fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Mesoblast Stock performance.
| Return On Equity | -0.18 | ||||
| Return On Asset | -0.0541 | ||||
| Operating Margin | (12.49) % | ||||
| Current Valuation | 1.76 B | ||||
| Shares Outstanding | 114.18 M | ||||
| Price To Earning | (5.90) X | ||||
| Price To Book | 3.63 X | ||||
| Price To Sales | 295.43 X | ||||
| Revenue | 5.9 M | ||||
| Gross Profit | (47.42 M) | ||||
| EBITDA | (56.08 M) | ||||
| Net Income | (87.96 M) | ||||
| Cash And Equivalents | 85.5 M | ||||
| Cash Per Share | 0.62 X | ||||
| Total Debt | 118.92 M | ||||
| Debt To Equity | 0.21 % | ||||
| Current Ratio | 1.90 X | ||||
| Book Value Per Share | 0.42 X | ||||
| Cash Flow From Operations | (48.46 M) | ||||
| Earnings Per Share | (1.05) X | ||||
| Market Capitalization | 1.14 B | ||||
| Total Asset | 669.15 M | ||||
| Retained Earnings | (908.76 M) | ||||
| Working Capital | 13.22 M | ||||
| Current Asset | 88.82 M | ||||
| Current Liabilities | 29.41 M | ||||
About Mesoblast Performance
By examining Mesoblast's fundamental ratios, stakeholders can obtain critical insights into Mesoblast's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Mesoblast is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (33.05) | (31.39) | |
| Return On Tangible Assets | (1.08) | (1.14) | |
| Return On Capital Employed | (0.14) | (0.13) | |
| Return On Assets | (0.13) | (0.12) | |
| Return On Equity | (0.16) | (0.17) |
Things to note about Mesoblast performance evaluation
Checking the ongoing alerts about Mesoblast for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Mesoblast help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Mesoblast generated a negative expected return over the last 90 days | |
| Mesoblast has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 5.9 M. Net Loss for the year was (87.96 M) with loss before overhead, payroll, taxes, and interest of (47.42 M). | |
| Mesoblast currently holds about 85.5 M in cash with (48.46 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.62. | |
| Mesoblast has a poor financial position based on the latest SEC disclosures | |
| Latest headline from gurufocus.com: Ryoncil Product Information Now Available in All Four Major Dru |
- Analyzing Mesoblast's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Mesoblast's stock is overvalued or undervalued compared to its peers.
- Examining Mesoblast's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Mesoblast's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Mesoblast's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Mesoblast's stock. These opinions can provide insight into Mesoblast's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mesoblast. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. To learn how to invest in Mesoblast Stock, please use our How to Invest in Mesoblast guide.You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mesoblast. If investors know Mesoblast will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mesoblast listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.05) | Revenue Per Share | Quarterly Revenue Growth (0.41) | Return On Assets | Return On Equity |
The market value of Mesoblast is measured differently than its book value, which is the value of Mesoblast that is recorded on the company's balance sheet. Investors also form their own opinion of Mesoblast's value that differs from its market value or its book value, called intrinsic value, which is Mesoblast's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mesoblast's market value can be influenced by many factors that don't directly affect Mesoblast's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mesoblast's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mesoblast is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mesoblast's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.